COMPANY

Bessor Pharma

Keywords: oncology cancer

Location: Framingham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.1M (SBIR Phase II 5R44DK111251-05, continuation, notice Jul 28, 2026). NIH RePORTER 5R44DK111251-05 (Jul 28, 2026)
Evidence (1 event)
- Jul 28, 2026 · NIH RePORTER 5R44DK111251-05
  Organization: BESSOR PHARMA, LLC; City/State: FRAMINGHAM, MA; Project number: 5R44DK111251-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 1099995; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a novel renalase agonist for the treatment of acute pancreatitis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 28, 2026 Grant Government grant — SBIR: $1.1M (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 4, 2025 Grant Government grant — SBIR: $903,732 (annual award, as published), announced Sep 4, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Last 2 years.

Jul 28, 2026 Government grant — SBIR: $1.1M (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 4, 2025 Government grant — SBIR: $903,732 (annual award, as published), announced Sep 4, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗